drugset / Trial / NCT00399971

Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia

NCT00399971 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Our hypothesis is that ex vivo activated immune cells would produce multiple known and unknown potent hematopoietic cytokines, working in concert, these cytokines help stem cell growth and differentiation. Additionally, these cells travel and home to bone marrow as well as spleen and liver involved in hematopoietic activities, where direct cell-cell contact may be beneficial.

Timeline

Start
2002-11
Primary completion
2009-06
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ex vivo immunotherapy Cell therapy — Intravenous

Indications